2022 ESMO Meeting Reporter | Supplements And Featured Publications

HRQOL Is Maintained With Nivolumab in Real-World Population of Pretreated mRCC

September 20, 2022

Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.

HRQoL Proves to Be Helpful Prognostic Factor for Cabozantinib/Nivolumab in Advanced RCC

September 14, 2022

Higher baseline and longitudinal evaluations of health-related quality of life prior to and during treatment with nivolumab and cabozantinib demonstrated an association with improved progression-free survival and overall survival in patients with advanced, treatment-naïve renal cell carcinoma.

Increased In-Situ and Immune Expression Enrich for Nivolumab/Ipilimumab Efficacy in Metastatic RCC

September 12, 2022

The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was shown to be associated with an increased response rate and prolonged progression-free survival with the combination of nivolumab and ipilimumab as frontline therapy in patients with metastatic renal cell carcinoma.

Nivolumab/Ipilimumab Boosting Following Nivolumab Monotherapy Increases Responses in Advanced RCC

September 11, 2022

A tailored approach utilizing the combination of nivolumab and ipilimumab as an immunotherapeutic boost following induction with single-agent nivolumab improved responses in the first and second line for patients with advanced renal cell carcinoma.